Molecular genetics diagnostic company Mainz Biomed partners with bio-analytics firm Liquid Biosciences, known for its AI analysis platform EMERGE. Building on EMERGE’s success in Mainz Biomed’s ColoFuture study, the collaboration expands to include the U.S. eAArly DETECT study and the FDA PMA trial (ReconAAsense). The goal is to enhance Mainz Biomed’s colorectal cancer screening tool using EMERGE’s advanced AI capabilities. The partnership aims to develop a next-generation, self-administered CRC screening solution and reflects a commitment to advancing innovative cancer detection products.
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE) to serve the biopharma and diagnostics industries along with academic institutions.
The collaboration builds upon Mainz Biomed’s initial utilization of EMERGE to analyze the Company’s ColoFuture study, which recently reported groundbreaking results including sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 80%. ColoFuture is an international multi-center clinical trial which assessed the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®, Mainz Biomed’s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. This proprietary family of mRNA biomarkers represents a potentially game-changing innovation in CRC screening as the portfolio has previously demonstrated the ability to detect CRC lesions, including advanced adenomas, a type of pre-cancerous polyp often attributed to this deadly disease.
Under the terms of the partnership, the utility of EMERGE in Mainz Biomed’s product development pipeline will be extended to include analysis of its eAArly DETECT study (the U.S. arm of the ColoFuture clinical trial), and the forthcoming U.S. pivotal FDA PMA trial (ReconAAsense) which, if successful, will enable Mainz Biomed to further advance its current test’s capabilities and commercialize a next-generation, gold standard, self-administered CRC screening tool. The eAArly DETECT clinical trial, a multi-center feasibility study is enrolling 265 subjects across 22 sites and remains on track to report results in Q4 2023. The goal at completion will result in a single fixed machine learning/AI-based algorithm, developed utilizing the evolutionary EMERGE platform, integrated into the next-generation product’s test report.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“As artificial intelligence continues to disrupt every aspect of the healthcare sector, we are excited to establish a robust partnership with a genuine leader in the field as we head into the final development stage of our next-generation CRC screening test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We look forward to continuing our highly productive partnership with the Liquid Biosciences team as we execute on our mission to bring the most effective self-administered cancer detection products to the market.”
Since launching the EMERGE bio-analytics platform, Liquid Biosciences is widely considered to be the premier analytical partner to the life sciences industry. Its technology has been deployed in over 170 projects for Big Pharma and emerging therapeutic and diagnostic companies covering biomarker discovery, clinical trial screening and post-FDA approval services such as patient treatment selection and optimal dosing regiments. Key attributes of EMERGE that make it superior to mainstream AI and machine learning analytical solutions include its computational speed, ability to handle millions of variables and operate agnostically, without any assumptions or constraints. It was designed as a scalable, unbiased methodology to produce transparent algorithms from complex data, without any prior assumptions. This enables the identification of variables with relatively low expression, but which may be functionally important because of the non-linear interactions pervasive in complex biologic systems.
“We are excited to extend our relationship with Mainz Biomed into a formal partnership as we take great pride in working with companies who represent disruptive innovation that will impact disease prevention and treatment,” commented Patrick Lilley, Chief Executive Officer of Liquid Biosciences. “The work Mainz Biomed is doing will be crucial to saving lives from a disease where mortality is driven by late detection. As such, we are very pleased to have the opportunity to play an integral role in helping it develop the next generation of its pioneering products.”
